Regeneron (REGN) Stock Forecast & Price Target

Compare

5,158 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

REGN Analyst Ratings

Strong Buy

19 Buy

5 Hold

0 Sell

Based on 24 analysts giving stock ratings to

Regeneron

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

REGN Stock 12 Month Forecast

Average Price Target

$875.30

▲(15.19% Upside)

Based on 24 Wall Street analysts offering 12 month price targets for Regeneron in the last 3 months. The average price target is $875.30 with a high forecast of $1,057.00 and a low forecast of $742.00. The average price target represents a 15.19% change from the last price of $759.86.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"487":"$487","1058":"$1,058","629.75":"$629.8","772.5":"$772.5","915.25":"$915.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1057,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.06K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":875.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$875.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":742,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$742.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[487,629.75,772.5,915.25,1058],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,790.81,811.2861538461538,831.7623076923077,852.2384615384615,872.7146153846154,893.1907692307692,913.666923076923,934.1430769230769,954.6192307692307,975.0953846153845,995.5715384615385,1016.0476923076923,1036.523846153846,{"y":1057,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,790.81,797.3092307692307,803.8084615384615,810.3076923076923,816.806923076923,823.3061538461538,829.8053846153846,836.3046153846153,842.803846153846,849.3030769230769,855.8023076923076,862.3015384615384,868.8007692307692,{"y":875.3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,790.81,787.0553846153846,783.3007692307692,779.5461538461539,775.7915384615384,772.036923076923,768.2823076923077,764.5276923076923,760.7730769230769,757.0184615384616,753.2638461538461,749.5092307692307,745.7546153846154,{"y":742,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":694.943,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":613.647,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":586.793,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":488.864,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":532.789,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":556.654,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":579.276,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":598.468,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":650.201,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":749.208,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":770.942,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":754.112,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":790.81,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$1,057

Average Price Target$875.30

Lowest Price Target$742.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gregory Renza

Truist Financial

―

Buy

―

Reiterated

03/10/26

Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN), Zevra Therapeutics (NASDAQ: ZVRA) and Cooper Co (NASDAQ: COO)

Louise Chen

Scotiabank

$770

Hold

1.33%

Upside

Reiterated

03/10/26

Scotiabank Sticks to Their Hold Rating for Regeneron (REGN)

Terence Flynn

Morgan Stanley

$769

Hold

1.20%

Upside

Reiterated

03/08/26

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), Hims & Hers Health (NYSE: HIMS) and Regeneron (NASDAQ: REGN)

Eliana Merle

Barclays

$787.5→$923

Buy

21.47%

Upside

Initiated

03/05/26

Regeneron initiated with an Overweight at BarclaysRegeneron initiated with an Overweight at Barclays

Brian Abrahams

RBC Capital

$745→$765

Hold

0.68%

Upside

Reiterated

03/02/26

Regeneron (REGN) Receives a Hold from RBC Capital

Geoff Meacham

Citi

$900

Buy

18.44%

Upside

Reiterated

02/25/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

John Newman

Canaccord Genuity

$1,057

Buy

39.10%

Upside

Reiterated

02/23/26

Canaccord Genuity Remains a Buy on Regeneron (REGN)

Yatin Suneja

Guggenheim

$865→$975

Buy

28.31%

Upside

Reiterated

02/08/26

Regeneron price target raised to $975 from $865 at GuggenheimRegeneron price target raised to $975 from $865 at Guggenheim

Cory Kasimov

Evercore ISI

$875

Buy

15.15%

Upside

Reiterated

02/02/26

Evercore ISI Keeps Their Buy Rating on Regeneron (REGN)

Chris Schott

J.P. Morgan

$850→$950

Buy

25.02%

Upside

Reiterated

02/02/26

Regeneron price target raised to $950 from $850 at JPMorganRegeneron price target raised to $950 from $850 at JPMorgan

Matthew Biegler

Oppenheimer

$750→$865

Buy

13.84%

Upside

Reiterated

02/02/26

Regeneron price target raised to $865 from $750 at OppenheimerRegeneron price target raised to $865 from $750 at Oppenheimer

Tazeen Ahmad

Bank of America Securities

$860

Buy

13.18%

Upside

Reiterated

02/02/26

Analysts Are Bullish on These Healthcare Stocks: Eton Pharmaceuticals (ETON), HealthStream (HSTM)

Brian Skorney

Robert W. Baird

$630→$742

Hold

-2.35%

Downside

Reiterated

02/02/26

Regeneron price target raised to $742 from $630 at BairdRegeneron price target raised to $742 from $630 at Baird

Mohit Bansal

Wells Fargo

$745→$800

Hold

5.28%

Upside

Reiterated

02/01/26

Regeneron price target raised to $800 from $745 at Wells FargoRegeneron price target raised to $800 from $745 at Wells Fargo

Carter Gould

Cantor Fitzgerald

$740→$800

Buy

5.28%

Upside

Reiterated

02/01/26

Regeneron price target raised to $800 from $740 at Cantor FitzgeraldRegeneron price target raised to $800 from $740 at Cantor Fitzgerald

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gregory Renza

Truist Financial

―

Buy

―

Reiterated

03/10/26

Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN), Zevra Therapeutics (NASDAQ: ZVRA) and Cooper Co (NASDAQ: COO)

Louise Chen

Scotiabank

$770

Hold

1.33%

Upside

Reiterated

03/10/26

Scotiabank Sticks to Their Hold Rating for Regeneron (REGN)

Terence Flynn

Morgan Stanley

$769

Hold

1.20%

Upside

Reiterated

03/08/26

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), Hims & Hers Health (NYSE: HIMS) and Regeneron (NASDAQ: REGN)

Eliana Merle

Barclays

$787.5→$923

Buy

21.47%

Upside

Initiated

03/05/26

Regeneron initiated with an Overweight at BarclaysRegeneron initiated with an Overweight at Barclays

Brian Abrahams

RBC Capital

$745→$765

Hold

0.68%

Upside

Reiterated

03/02/26

Regeneron (REGN) Receives a Hold from RBC Capital

Geoff Meacham

Citi

$900

Buy

18.44%

Upside

Reiterated

02/25/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

John Newman

Canaccord Genuity

$1,057

Buy

39.10%

Upside

Reiterated

02/23/26

Canaccord Genuity Remains a Buy on Regeneron (REGN)

Yatin Suneja

Guggenheim

$865→$975

Buy

28.31%

Upside

Reiterated

02/08/26

Regeneron price target raised to $975 from $865 at GuggenheimRegeneron price target raised to $975 from $865 at Guggenheim

Cory Kasimov

Evercore ISI

$875

Buy

15.15%

Upside

Reiterated

02/02/26

Evercore ISI Keeps Their Buy Rating on Regeneron (REGN)

Chris Schott

J.P. Morgan

$850→$950

Buy

25.02%

Upside

Reiterated

02/02/26

Regeneron price target raised to $950 from $850 at JPMorganRegeneron price target raised to $950 from $850 at JPMorgan

Matthew Biegler

Oppenheimer

$750→$865

Buy

13.84%

Upside

Reiterated

02/02/26

Regeneron price target raised to $865 from $750 at OppenheimerRegeneron price target raised to $865 from $750 at Oppenheimer

Tazeen Ahmad

Bank of America Securities

$860

Buy

13.18%

Upside

Reiterated

02/02/26

Analysts Are Bullish on These Healthcare Stocks: Eton Pharmaceuticals (ETON), HealthStream (HSTM)

Brian Skorney

Robert W. Baird

$630→$742

Hold

-2.35%

Downside

Reiterated

02/02/26

Regeneron price target raised to $742 from $630 at BairdRegeneron price target raised to $742 from $630 at Baird

Mohit Bansal

Wells Fargo

$745→$800

Hold

5.28%

Upside

Reiterated

02/01/26

Regeneron price target raised to $800 from $745 at Wells FargoRegeneron price target raised to $800 from $745 at Wells Fargo

Carter Gould

Cantor Fitzgerald

$740→$800

Buy

5.28%

Upside

Reiterated

02/01/26

Regeneron price target raised to $800 from $740 at Cantor FitzgeraldRegeneron price target raised to $800 from $740 at Cantor Fitzgerald

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Regeneron

3 Months

xxx

Success Rate

16/26 ratings generated profit

Average Return

+3.77%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +3.77% per trade.

1 Year

David RisingerLeerink Partners

Success Rate

21/26 ratings generated profit

Average Return

+19.98%

a rating ―

Copying David Risinger's trades and holding each position for 1 Year would result in 80.77% of your transactions generating a profit, with an average return of +19.98% per trade.

2 Years

xxx

Success Rate

21/26 ratings generated profit

Average Return

+21.10%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 80.77% of your transactions generating a profit, with an average return of +21.10% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

REGN Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, REGN has received 36 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. REGN average Analyst price target in the past 3 months is 875.30.

Each month's total comprises the sum of three months' worth of ratings.

REGN Financial Forecast

REGN Earnings Forecast

Next quarter’s earnings estimate for REGN is $9.13 with a range of $5.77 to $12.75. The previous quarter’s EPS was $11.44. REGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year REGN has Performed in-line its overall industry.

REGN Sales Forecast

Next quarter’s sales forecast for REGN is $3.45B with a range of $3.06B to $3.95B. The previous quarter’s sales results were $3.88B. REGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year REGN has Performed in-line its overall industry.

REGN Stock Forecast FAQ

What is REGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Regeneron Pharmaceuticals’s 12-month average price target is 875.30.

What is REGN’s upside potential, based on the analysts’ average price target?

Regeneron Pharmaceuticals has 15.19% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is REGN a Buy, Sell or Hold?

Regeneron Pharmaceuticals has a consensus rating of Strong Buy which is based on 19 buy ratings, 5 hold ratings and 0 sell ratings.

What is Regeneron Pharmaceuticals’s price target?

The average price target for Regeneron Pharmaceuticals is 875.30. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $1,057.00 ,the lowest forecast is $742.00. The average price target represents 15.19% Increase from the current price of $759.86.

What do analysts say about Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 24 Wall Streets Analysts.

How can I buy shares of REGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Regeneron (REGN) Stock Forecast & Price Target

REGN Analyst Ratings

REGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Regeneron

REGN Analyst Recommendation Trends

REGN Financial Forecast

REGN Earnings Forecast

REGN Sales Forecast

REGN Stock Forecast FAQ

Detailed List of Analyst Forecasts